(ASRT) Assertio Holdings, Inc. Porters Five Forces Research |
Fully Editable: Tailor To Your Needs In Excel Or Sheets
Professional Design: Trusted, Industry-Standard Templates
Investor-Approved Valuation Models
MAC/PC Compatible, Fully Unlocked
No Expertise Is Needed; Easy To Follow
(ASRT) Assertio Holdings, Inc. Complete Analysis Pack
Elevate Your Analysis with the Complete Porter's Five Forces Analysis
This Assertio Holdings, Inc. Porter's Five Forces Analysis helps you quickly assess the company’s competitive environment, including rivalry, buyer power, supplier power, substitutes, and new entrants. The page already shows a real preview of the analysis, so you can see the actual content before buying. Purchase the full version to get the complete ready-to-use report.
Suppliers Bargaining Power
API sourcing dependence
Assertio relies on third-party API and finished-dose makers, so supplier power is high when only a few plants meet FDA and quality rules. That matters most for niche brands like INDOCIN and SPRIX, where any disruption can hit supply fast. Fewer qualified sources can mean higher unit costs, longer lead times, and tighter margins.
Regulatory compliance leverage
Pharmaceutical suppliers face FDA and cGMP rules, so only a narrow pool can qualify, which boosts supplier leverage. If Assertio switches vendors, the move can trigger revalidation, stability testing, or reformulation, raising cost and delay. That friction lets suppliers push for better pricing, tighter terms, and longer contracts.
Contract manufacturing reliance
Assertio Holdings, Inc. relies on contract manufacturers, so supplier power rises when capacity is tight or one plant serves multiple customers. FDA reported 323 active U.S. drug shortages in 2024, which shows how fragile pharma supply can get. That makes continuity critical for Assertio’s legacy brands, where even a short delay can disrupt steady sales.
Packaging and logistics inputs
Packaging, labeling, freight, and controlled distribution can still push Assertio Holdings, Inc. costs up even though they are not the drug itself. Supplier power is moderate because shortages or higher cold-chain storage and freight rates can pass through fast, and that bites harder when mature brands and generic pressure already squeeze margins.
In FY2025, this matters more because cost swings in non-drug inputs can erode gross margin on low-growth products. If packaging lead times stretch or logistics prices rise, Assertio has limited room to absorb it without hurting profit.
- Non-drug inputs still affect margin.
- Freight and storage costs can pass through.
- Controlled distribution can add supplier power.
- Pressure rises when products are mature.
Limited bargaining offsets
Assertio Holdings, Inc. has a focused portfolio, so it lacks the buying scale that can दब pressure on suppliers. That lowers purchase-volume leverage, but branded specialty products also support steadier, longer-term supplier ties.
Supplier power is moderate, with the main risk coming from quality-qualified manufacturing limits and the need for compliant production sites.
- Focused portfolio weakens volume leverage
- Branded drugs support stable supplier links
- Quality-qualified supply is the key constraint
Assertio’s Supplier Power Is Tightening
Supplier power is moderate to high for Assertio Holdings, Inc. because FDA and cGMP rules narrow the pool of qualified API and finished-dose makers. FDA reported 323 active U.S. drug shortages in 2024, which shows how fast supply risk can tighten.
That matters most for niche brands like INDOCIN and SPRIX, where switching vendors can trigger revalidation, stability work, and delays. A focused portfolio also weakens Assertio Holdings, Inc.’s volume leverage.
So higher freight, packaging, or plant-capacity costs can pass through faster and squeeze margin on mature products.
| Factor | Latest data | Impact |
|---|---|---|
| FDA shortages | 323 in 2024 | Higher supply risk |
| Supplier base | Narrow, qualified | More leverage for suppliers |
| Portfolio mix | Focused legacy brands | Weak buying power |
What is included in the product
Detailed Word Document
Assesses the competitive forces shaping Assertio Holdings, Inc.’s pricing power, margins, and growth risks.
Customizable Excel Spreadsheet
A quick, board-ready view of Assertio’s competitive pressures—so you can spot risks and opportunities fast.
Reference Sources
Assertio Holdings, Inc. Reference Sources provide a credible audit trail that strengthens trust and speeds decision-making.
Customers Bargaining Power
Payer and formulary pressure
In pharma, Assertio Holdings, Inc. faces payer power more than patient choice: three major PBMs and large health systems can demand rebates, preferred placement, or exclusion. In 2025, that kind of formulary control can move volume fast and squeeze net pricing, especially for products with close substitutes.
Physician and hospital gatekeepers
Doctors, hospitals, and clinics control most of Assertio Holdings, Inc.'s prescribing and buying decisions, so their gatekeeping can quickly shift volume away from any product that looks interchangeable. In pain and inflammation, where generic options are often cheaper, that weakens pricing power and puts pressure on margins. The result is a buyer base that can push back hard unless Assertio proves clear clinical or economic value.
Patient sensitivity to out-of-pocket cost
Patients are very price sensitive: Medicare Part D now caps annual out-of-pocket drug spending at $2,000 in 2025, but many commercial plans still use tiered copays and prior auth. For chronic, repeat-use therapies, higher cost sharing can cut adherence and lower refill volume. That makes favorable formulary placement critical for Assertio Holdings, Inc. demand.
Generic and branded alternatives
Assertio Holdings, Inc. faces strong buyer power because customers can pick from many NSAIDs, migraine drugs, and rheumatoid arthritis therapies. In 2024, Assertio reported about $151 million in net sales, so even small switches can matter. With so many branded and generic substitutes, buyers can press on price and move away fast.
- Many therapeutic substitutes
- Low switching cost for buyers
- Greater pricing pressure on Assertio
Concentrated channel influence
Customer power is high to moderate for Assertio Holdings, Inc. because a few large payers and distributors can drive a big share of volume. In U.S. pharmacy benefits, the top 3 PBMs have controlled roughly 80% of covered lives, so they can push for lower rebates and tighter contract terms.
- Few buyers, big leverage.
- Rebates pressure net price.
- Channel mix changes bargaining power.
High Buyer Power Still Pressures Assertio’s Pricing
Customer power is high for Assertio Holdings, Inc.: few PBMs and health systems can force rebates, exclusions, and tighter access. With the Medicare Part D out-of-pocket cap at $2,000 in 2025 and the top 3 PBMs controlling about 80% of covered lives, buyers can still pressure net pricing. Generic-heavy categories keep switching easy.
| Metric | 2025 |
|---|---|
| Medicare Part D OOP cap | $2,000 |
| Top 3 PBMs covered lives | ~80% |
| Assertio net sales | $151M |
Preview Before You Purchase
Assertio Holdings, Inc. Porter's Five Forces Analysis
This preview shows the exact Assertio Holdings, Inc. Porter's Five Forces Analysis you'll receive after purchase—no edits, no placeholders, no surprises. The document is fully formatted and ready to use the moment your payment is complete. What you see here is the same professional file delivered instantly for download.
Rivalry Among Competitors
Mature therapeutic categories
Assertio Holdings, Inc. faces high rivalry because pain, inflammation, migraine, and autoimmune care are mature markets with many branded and generic options. In migraine alone, over 10 CGRP-targeted products have raised price and access pressure, while pain and inflammation lines are crowded with low-cost substitutes.
That leaves little room to stand out unless a product delivers clear clinical benefit, easier dosing, or better payer access. Without that edge, competition shifts to rebates, formulary wins, and contracting, which squeezes margins.
Brand erosion risk
Brand erosion is a real risk for Assertio Holdings, Inc. because several products are legacy brands that can fade as physicians and payers switch to newer or cheaper therapies. Rival firms can win share if they offer better formulary access, so Assertio has to keep spending on promotion and payer positioning to defend loyalty.
Generic and multi-source competition
Generic and multi-source competition is strong in Assertio Holdings, Inc.'s NSAID and pain markets because generics now fill about 90% of U.S. prescriptions, so buyers can switch fast to lower-cost options. That price pressure compresses margins and makes older, less differentiated products far harder to defend.
In pain care, rival products often look similar on efficacy, so contracts and rebates matter more than brand strength. For Assertio Holdings, Inc., that keeps rivalry high and limits pricing power.
Specialty pharma peers
Assertio Holdings, Inc. faces specialty pharma peers in pain, migraine, and rheumatology, where rivals compete on data, payer access, and channel reach, not just price. That makes the fight both promotional and commercial, with wins often tied to formulary placement and prescriber demand.
In this niche market, even small share shifts can matter because branded specialty drugs usually defend access through evidence and contracting. So the rivalry stays intense, and marketing spend and discounting pressure can move fast.
- Competes on clinical evidence
- Competes on distribution access
- Competes on payer contracting
- Price is only one lever
Promotion and access intensity
Competitive rivalry is moderate to high because Assertio Holdings, Inc. sells in markets where payer access, physician education, and channel execution can shift volume fast. When a rival funds more sales support or wins better formulary access, Assertio can lose prescriptions quickly, especially in low-differentiation products.
Payer contracts drive near-term volume.
Sales support can swing share fast.
Low differentiation raises churn risk.
Assertio Faces Intense Price Wars in Crowded Pain and Migraine Markets
Competitive rivalry is high for Assertio Holdings, Inc. because pain, migraine, and inflammation markets are crowded with branded and generic rivals, and price is often the main weapon. U.S. generics fill about 90% of prescriptions, so switching is easy and margin pressure is strong. In migraine, 10+ CGRP products add even more payer and rebate pressure.
| Factor | Data |
|---|---|
| U.S. generic Rx share | ~90% |
| CGRP migraine rivals | 10+ |
| Rivalry level | High |
Substitutes Threaten
Therapeutic class alternatives
Patients and prescribers can switch among dozens of pain, migraine, arthritis, and anti-inflammatory drug classes, including NSAIDs, triptans, CGRP therapies, and corticosteroids. If another option offers lower GI risk, simpler dosing, or lower out-of-pocket cost, it can replace Assertio Holdings, Inc. products fast. This keeps substitution pressure high in a market with many therapeutic choices and no 1-drug lock-in.
Non-drug treatment options
CDC data show about 24% of U.S. adults reported chronic pain in 2023, and migraine affects about 14% of people worldwide. Physical therapy, lifestyle changes, procedures, and behavioral therapy can cut drug use, so some patients can partly replace medication. When payers push lower-cost non-pharmacologic care, the substitute threat rises for Assertio Holdings, Inc.'s pain and migraine products.
Over-the-counter alternatives
OTC pain relievers keep pressure on Assertio Holdings, Inc. because mild pain often shifts to ibuprofen, acetaminophen, or self-care instead of prescription drugs. This matters most in lower-severity pain, where prescription strength is not needed and OTC shelf space is broad. That can cap demand for branded NSAID products, especially when price-sensitive patients can switch fast.
Newer targeted therapies
In migraine, CGRP-targeted drugs have changed prescribing fast; the class now has 10+ FDA-approved options, and its convenience can pull patients away from older therapies. Rheumatoid arthritis affects about 1.3 million US adults, and newer JAK inhibitors and biologics can beat older pain-focused drugs on control and dosing, so substitution pressure is strongest in chronic use.
- 10+ CGRP options raise migraine substitution risk
- 1.3 million US RA patients widen switch risk
- Better dosing can move prescribers fast
Route and convenience substitutes
Route and convenience substitutes are a real threat for Assertio Holdings, Inc. because patients often choose the form that is easiest to use, not just the one with strong efficacy. Oral drugs still dominate U.S. prescriptions, while injectables are often picked when they give faster relief or better adherence, so any easier-delivered rival can pull demand away from Assertio’s formulations.
That matters most in pain and neurology, where comfort and speed can outweigh brand loyalty. If a substitute cuts administration time or avoids swallowing issues, it can win even at a higher price.
- Convenience can beat efficacy in practice.
- Oral and injectable routes are key substitutes.
- Faster relief can shift patient demand.
High Substitute Risk Pressures Assertio’s Pricing Power
Threat of substitutes is high for Assertio Holdings, Inc. because patients can switch to OTC analgesics, CGRP migraine drugs, biologics, or non-drug care if cost, dosing, or side effects look better. U.S. chronic pain is about 24% of adults, and migraine affects about 14% of people worldwide, so substitution choices stay wide. Convenience and payer pressure keep switch risk high.
| Substitute | Why it wins |
|---|---|
| OTC pain relievers | Low cost |
| CGRP therapies | Better migraine control |
| PT/lifestyle care | Less drug use |
Entrants Threaten
High regulatory barriers
High regulatory barriers make Assertio Holdings, Inc.’s markets hard to enter: drug development usually takes 10-15 years, and Tufts estimates the cost at about $2.6 billion per approved drug. New entrants must clear FDA review, clinical trials, and cGMP manufacturing rules, so they cannot launch fast or cheap. That protects incumbents like Assertio Holdings, Inc. from casual entry.
Capital and evidence requirements
Launching a pharmaceutical product needs heavy cash upfront: Phase 1-3 trials often run from tens of millions to more than $100 million, and an FDA New Drug Application fee was $4,031,489 in FY2025. New entrants also need strong clinical data to prove safety, efficacy, and payer value, or they face weak reimbursement and slow uptake. Those costs and proof hurdles cut the pool of credible challengers to Assertio Holdings, Inc.
Established distribution access
Established distribution access keeps the threat of new entrants low for Assertio Holdings, Inc. New companies must win payer contracts, pharmacy access, and prescriber trust before sales can build, and those channels are already tied to known brands and long-standing relationships. Without that access, even a strong product can stall before it reaches patients.
Brand and reputation advantage
Legacy pain brands win on familiarity: physicians often keep using products they know, especially where safety matters. For new entrants, building trust can take 10+ years and costly trials, while Assertio still has established brands and payer links despite portfolio maturity.
- Physician familiarity lowers switching.
- Safety risk raises proof needs.
- Credibility takes years, not months.
Moderate niche entry risk
Threat of new entrants is moderate for Assertio Holdings, Inc. Broad-scale entry is hard, but niche specialty players can still enter with focused products, licensing deals, and outsourced contract manufacturing or commercialization. That keeps barriers real, but not high enough to rule out challengers, especially in small therapeutic niches.
- Focused niche entrants can still appear.
- Outsourcing lowers launch barriers.
- Threat stays moderate, not negligible.
High Bar to Entry Keeps Assertio's Competition Risk Low
Threat of new entrants for Assertio Holdings, Inc. stays low to moderate: drug development can take 10-15 years and cost about $2.6 billion per approved drug, while the FDA New Drug Application fee was $4,031,489 in FY2025.
New players still need FDA proof, payer access, and physician trust, which slows launch and weakens uptake.
| Barrier | Latest data |
|---|---|
| Drug development time | 10-15 years |
| Cost per approved drug | $2.6 billion |
| NDA fee FY2025 | $4,031,489 |
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.